Literature DB >> 2157771

Evaluation of enzyme-linked immunosorbent assays with two synthetic peptides of Epstein-Barr virus for diagnosis of infectious mononucleosis.

A Linde1, B Kallin, J Dillner, J Andersson, L Jägdahl, A Lindvall, B Wahren.   

Abstract

To diagnose infectious mononucleosis caused by Epstein-Barr virus (EBV), a peptide from the EBV nuclear antigen (EBNA) 1 (p107) and an EBNA 2 peptide (polyproline) were used as antigens in enzyme-linked immunosorbent assays for IgG and IgM. Well-characterized serum samples (360) from healthy individuals and patients with EBV or cytomegalovirus infections were examined. The p107 IgG and IgM assays were also tested with serum from 1000 patients with suspected EBV-related disorders. The p107 and polyproline IgG assays were 100% specific for EBV seropositivity. Low p107 IgG titers (less than 1000) were found in 98% of patients with EBV infectious mononucleosis but also in 18% of patients with other diseases. A p107-to-polyproline IgG ratio of less than 1 was 98% specific for EBV infectious mononucleosis; sensitivity was 86%. In EBV capsid antigen-IgG seropositive patients, a p107 IgG titer of less than 1000 together with a p107 IgG-to-IgM ratio of less than 1 was 98% sensitive and specific for EBV infectious mononucleosis. Thus, this ratio appears adequate to measure EBNA antibodies for diagnosis of EBV mononucleosis.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2157771     DOI: 10.1093/infdis/161.5.903

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  17 in total

1.  Herpesvirus serology, aberrant specific immunoglobulin G2 and G3 subclass patterns and Gm allotypes in individuals with low levels of IgG3.

Authors:  A Linde; R Söderström; C I Smith; M Sällberg; H Dahl; R Grubb; J Björkander; L Hammarström
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

Review 2.  Routine Epstein-Barr virus diagnostics from the laboratory perspective: still challenging after 35 years.

Authors:  Ralf D Hess
Journal:  J Clin Microbiol       Date:  2004-08       Impact factor: 5.948

3.  A prospective study of Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma.

Authors:  Kimberly A Bertrand; Brenda M Birmann; Ellen T Chang; Donna Spiegelman; Jon C Aster; Shumin M Zhang; Francine Laden
Journal:  Blood       Date:  2010-07-20       Impact factor: 22.113

4.  Epitope mapping of B-cell determinants on the 15-kilodalton lipoprotein of Treponema pallidum (Tpp15) with synthetic peptides.

Authors:  R E Baughn; M Demecs; L H Taber; D M Musher
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

5.  Reactivation of latent Epstein Barr virus infection induces remission of splenic lymphoma with villous lymphocytes.

Authors:  Markus Hansson; Annika Linde; Inge Olsson
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

6.  Epstein-Barr virus nuclear antigen 1 linear epitopes that are reactive with immunoglobulin A (IgA) or IgG in sera from nasopharyngeal carcinoma patients or from healthy donors.

Authors:  H M Cheng; Y T Foong; C K Sam; U Prasad; J Dillner
Journal:  J Clin Microbiol       Date:  1991-10       Impact factor: 5.948

Review 7.  Serological diagnosis of Epstein-Barr virus infection: Problems and solutions.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2012-02-12

8.  Increased risk of malignant lymphoma indicated by elevated Epstein-Barr virus antibodies--a prospective study.

Authors:  T Lehtinen; J Lumio; J Dillner; M Hakama; P Knekt; M Lehtinen; L Teppo; P Leinikki
Journal:  Cancer Causes Control       Date:  1993-05       Impact factor: 2.506

9.  Use of enzyme-linked immunosorbent assays with chimeric fusion proteins to titrate antibodies against Epstein-Barr virus nuclear antigen 1.

Authors:  N Inoue; J Kuranari; S Harada; H Nakajima; M Ohbayashi; Y Nakamura; N Miyasaka; K Ezawa; F Ban; K Yanagi
Journal:  J Clin Microbiol       Date:  1992-06       Impact factor: 5.948

10.  Comparative evaluation of nine kits for rapid diagnosis of infectious mononucleosis and Epstein-Barr virus-specific serology.

Authors:  M Linderholm; J Boman; P Juto; A Linde
Journal:  J Clin Microbiol       Date:  1994-01       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.